Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07391280

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department — Recruiting • Non-phase study • Oncology • NCT07391280.

📅 01 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07391280
Sponsor
NHS Greater Glasgow and Clyde
Start
2026-05-25
ClinicaliQ Trial Snapshot
  • Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department — Recruiting • Non-phase study • Oncology • NCT07391280.
  • What is being tested: A computer programme designed to assist emergency department clinicians in earlier recognition and diagnosis of three major conditions—cancer, COPD, and heart failure—by analysing patient presentations and clinical data.
  • Patient eligibility overview: The study recruits adult patients presenting to the Emergency Department at Queen Elizabeth University Hospital; specific inclusion/exclusion criteria would be applied based on symptoms suggestive of cancer, COPD, or heart failure.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays. We want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.

Eligibility Snapshot
  • : Unconsented Use of Harrison CXR Algorithm in Emergency Department (ED): * Frontal Chest X-Ray (CXR) (AP or PA) acquired in the Queen Elizabeth University Hospital (QEUH) ED * Patients aged 18 or over * Appropriate meta data (DICOM) to allow for Harrison CXR processing and secondary capture report provision. Patient Focus Groups: * Aged 18 or over * Able to provide written, informed consent in English. Clinician Focus Groups: * Aged 18 or over * Able to provide written, informed consent in English. * Working as a doctor, advanced nurse practitioner or advanced clinical practitioner in ED, radiology or downstream medical specialties * For post-implementation focus groups only, must have at least 4 months experience of working with Harrison CXR algorithm. Diagnostic Clinic: * Patients without terminal illness or advanced frailty * Usual healthcare provider based in NHS GGC

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
AI to speed up cancer diagnosis for millions of NHS patients
Oncology · NHS England · 10 Jun 2026
AI technologies are being implemented across the NHS to accelerate cancer diagnosis and reduce current waiting times for patients requiring diagnostic assessment.…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Clinical Brief
‘Quick skin cancer pathway the best birthday gift’
Oncology · BBC Health · 09 Sep 2026
Key Takeaways for Clinical Practice Early referral through skin cancer fast-track pathways enables rapid diagnosis and treatment, improving outcomes for melanoma patients
View brief →